<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056599</url>
  </required_header>
  <id_info>
    <org_study_id>PRS-2</org_study_id>
    <nct_id>NCT03056599</nct_id>
  </id_info>
  <brief_title>Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma</brief_title>
  <official_title>Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presage Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Presage Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study in patients with localized or metastatic soft tissue sarcoma
      undergoing surgery to determine how sarcoma in situ responds to injected microdoses of
      anti-cancer therapeutics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, pilot study designed to test the feasibility of using the CIVO
      (Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for
      percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection
      surgery will be injected one to three days prior to surgery using the CIVO device. Minute
      volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer
      agents will be percutaneously injected in a columnar fashion through each of 8 needles into a
      single enlarged solid tumor. Following the patient's biopsy surgery or tumor resection
      surgery, the injected portion and a small uninjected portion will be used to determine the in
      situ drug response in the tumor. None of the data from this evaluation will be shared with
      patients or used to make clinical decisions. Study clinicians will have access to the
      patient's health record for 1 year after the study to monitor patient treatment responses.
      Such information will be used to help evaluate the correlation between clinical response and
      tumor response assessed via CIVO.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of fraction of cells positive for apoptosis and drug target engagement biomarkers around injected drugs</measure>
    <time_frame>1-3 days after microinjection</time_frame>
    <description>Analysis will be performed to determine if there is a difference in responses caused by each drug versus the vehicle control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to pain</measure>
    <time_frame>up to 28 days after microinjection</time_frame>
    <description>Relationship of AE to study device or study procedure will be determined using an AE Relatedness Grading System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation and intra-class correlation coefficient of fraction of cells around injected drug in multiple tumor planes</measure>
    <time_frame>1-3 days after microinjection</time_frame>
    <description>Analysis will be performed for fraction of cells positive for apoptosis and drug target engagement biomarkers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Soft Tissue Sarcoma Adult</condition>
  <arm_group>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one to three days prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple drug microinjection</intervention_name>
    <description>This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.</description>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Interferon gamma</other_name>
    <other_name>Pembrolizumab</other_name>
    <other_name>Ipilimumab</other_name>
    <other_name>Interferon alfa-2B</other_name>
    <other_name>Bortezomib</other_name>
    <other_name>Aldesleukin</other_name>
    <other_name>Trabectedin</other_name>
    <other_name>Eribulin</other_name>
    <other_name>Olaratumab</other_name>
    <other_name>Atezolizumab</other_name>
    <other_name>Durvalumab</other_name>
    <other_name>Avelumab</other_name>
    <other_name>Nivolumab</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CIVO device</intervention_name>
    <description>Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO™ device in soft tissue sarcoma patients undergoing surgery.</description>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or over.

          -  At least one suspected soft tissue sarcoma tumor that is considered by the
             investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm
             in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm
             in shortest dimension for patients undergoing an excisional biopsy/tumor resection.
             Tumors should not be selected if the Investigator believes them to be necrotic or
             exhibit signs of radiation-induced fibrosis.

          -  Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor
             being injected.

          -  ECOG performance status of 0-2 (or a Karnofsky performance status of &gt;50%)

          -  Labs required for enrollment (prior to microinjection):

               -  Absolute neutrophil count &gt; 1000/mm3

               -  Platelet count &gt; 50,000/mm3

               -  Hematocrit &gt; 25%

               -  Creatinine &lt;3.0 mg/dl

               -  Total Bilirubin &lt;4.0 mg/dl

               -  Bilirubin &lt;4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal

               -  PT and PTT ≤ 1.5 times the upper limit of normal

        Exclusion Criteria:

          -  Subjects with active fungal, viral, or bacterial infections.

          -  Pregnant women.

          -  Inability to give informed consent.

          -  Current treatment with anticoagulation such as warfarin or low-molecular-weight
             heparin.

          -  Tumors near critical structures such as those located near or in the brain or spine.
             This assessment will be determined by the treating clinician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Deutsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Gundle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science University (OHSU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seth Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/SCCA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Presage Clinical Operations Team</last_name>
    <phone>800-530-5404</phone>
    <email>clinops@presagebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monter Cancer Center (Northwell Health)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sierra Bertolone-Smith</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Gundle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Davis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Hayden, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yee-Cheen Doung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance (SCCA)/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vivo drug sensitivity</keyword>
  <keyword>personalized medicine</keyword>
  <keyword>precision oncology</keyword>
  <keyword>in vivo oncology</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>microinjection</keyword>
  <keyword>microdosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
    <mesh_term>Olaratumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

